Background and Purpose
Since the SAMMPRIS trial, aggressive medical management (AMM), which includes dual antiplatelet therapy (DAPT) and high-dose statin (HDS) therapy, is recommended for patients with symptomatic ICAD. However, limited data on the “real-world” application of this regimen exist. We hypothesized that recurrent stroke risk among patients treated with AMM is similar to the medical arm of the SAMMPRIS cohort.
Methods
Using a prospective registry, we identified all patients admitted between August 2012 and March 2015 with 1) confirmed ischemic stroke (IS) or transient ischemic attack (TIA); 2) independently adjudicated symptomatic ICAD; and 3) follow-up at 30 days. We analyzed 30-day risk of recurrent IS stratified by treatment: 1) AMM: DAPT plus HDS therapy, 2) HDS alone, and 3) DAPT alone. We also assessed 30-day risk among patients who met prespecified SAMMPRIS eligibility criteria.
Results
Among 99 patients who met study criteria (51.5% male, 54.5% black, mean age 68.2 ± 11.2 years), 49 (48.5%) patients were treated with AMM, 69 (69.7%) with DAPT, and 73 (73.7%) with HDS therapy. At 30 days, 20 (20.2%) patients had recurrent strokes in the territory of stenosis. Compared to the risk in the medical arm of SAMMPRIS (4.4%), the 30-day risk of recurrent stroke was 20.4% in AMM patients, 21.5% in HDS patients, 22.4% in DAPT patients, and 23.2% in SAMMPRIS-eligible patients (all p<0.001).
Conclusions
Recurrent stroke risk within 30 days in patients with symptomatic ICAD was higher than that observed in the medical arm of SAMMPRIS even in the subgroup receiving aggressive medical management. Replication of the SAMMPRIS findings requires further prospective study.